Form 4: Keros Therapeutics Director Tomer Kariv Acquires 10,000 Stock Options

Director Tomer Kariv of Keros Therapeutics acquired 10,000 stock options at an exercise price of $46.31 on May 30, 2024.

Summary

• Tomer Kariv, a director of Keros Therapeutics, acquired 10,000 stock options on May 30, 2024.
• The exercise price of these options is $46.31.
• The options vest in equal quarterly installments over 12 months, fully vesting by the Issuer's 2025 annual meeting of stockholders, contingent on continued service.
• Following the transaction, Kariv directly owns 10,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects a standard transaction of stock options to a director, which is neither overtly positive nor negative.

Positives

• A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedule indicates an expectation of continued service from the reporting person through the company's 2025 annual meeting of stockholders.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation.

Stakeholder Impact

• The acquisition of stock options by a director could be perceived positively by shareholders, signaling confidence in the company's future.

Key Dates